SecBot SecBot
Biotech Drug Report Generated Nov 14, 2026

ozekibart

INBX·Inhibrx Biosciences, Inc.
BULLISH
Drug Impact Rating8/10
Trial phase
Filed/PDUFA (BLA accepted by FDA)
Time to market
PDUFA goal date is April14, 2027. If approved, launch could follow shortly after, positioning ozekibart as the first FDA-approved systemic therapy for conventional chondrosarcoma.
Why 8/10
The next hard, dated catalyst is the FDA PDUFA decision for ozekibart in unresectable or metastatic conventional chondrosarcoma on April14, 2027. This represents a binary approval/rejection decision on the company's lead asset within ~5 months, warranting an 8 on the impact scale.
Actionable Insight BULLISH

The next hard catalyst is the FDA PDUFA decision for ozekibart in conventional chondrosarcoma on April 14, 2027. An approval would make ozekibart the first FDA-approved systemic therapy for this rare bone cancer and likely drive a significant re-rating. A Complete Response Letter would be a severe setback given ozekibart is Inhibrx's lead asset. In the interim, watch the pace of sales under the newly filed $150M ATM equity offering and any updates on the accelerated approval pathway discussion for Ewing sarcoma.

Price Chart

Loading chart...

Executive Summary

Ozekibart (formerly INBRX-109) is Inhibrx Biosciences' lead drug candidate, a precision-engineered antibody that activates death receptor 5 (DR5) to trigger cancer cell death. Its BLA for unresectable or metastatic conventional chondrosarcoma -- a rare bone cancer with no approved systemic therapies -- was accepted by the FDA in June2026 with a PDUFA date of April14, 2027. A registrational trial showed ozekibart reduced the risk of disease progression or death by 52% versus placebo. The stock surged over 70% on that readout in October2025. Inhibrx filed a $150M at-the-market equity offering on November13,2026 alongside Q3 results showing $199.5M cash, $275M debt, and a $38.7M quarterly burn. Short interest is elevated at ~23% of shares outstanding. Analyst consensus is strongly bullish with a mean price target of $266.67, implying ~204% upside from the recent $87.75 close. CEO Mark Lappe made ~$1.5M in open-market purchases in September-October2026.

How It Works

Ozekibart is a precision-engineered antibody that activates death receptor5 (DR5) on the surface of cancer cells. DR5 activation triggers a self-destruct signal (apoptosis) preferentially in tumor cells, causing them to die. It is designed as a tetravalent (four-armed) antibody to more potently cluster and activate DR5 compared to natural or simpler antibodies.

Trial Status

Positive registrational Phase 2/3 topline results announced October23,2025. BLA submitted in Q22026 and accepted by FDA with no filing review issues on June15,2026. PDUFA goal date set for April14,2027. Also in Phase1/2 for late-line colorectal cancer and Phase2 for refractory Ewing sarcoma.

The Two-Sided Case

▲ Bull Case6
Registrational trial showed ozekibart reduced the risk of disease progression or death by 52% vs placebo, a clinically meaningful result in a setting with no approved therapies.
BLA was accepted by FDA with no filing review issues identified, and a PDUFA date is set for April14,2027 -- a clear binary catalyst within ~5 months.
If approved, ozekibart would be the first and only FDA-approved systemic treatment for unresectable or metastatic conventional chondrosarcoma, a clear orphan-drug market.
CEO Mark Lappe purchased ~$1.5M worth of INBX stock on the open market in September-October2026, signaling insider confidence.
Analyst consensus is bullish: 8 Buy/Strong Buy vs 2 Hold, with a mean price target of $266.67 (204% implied upside from the $87.75 close).
Ozekibart also has early clinical data in late-line colorectal cancer and an ongoing accelerated approval discussion with FDA for refractory Ewing sarcoma, adding pipeline optionality.
▼ Bear Case5
Inhibrx has $199.5M cash vs $275M in debt and a $38.7M quarterly burn, requiring the newly filed $150M ATM (filed Nov13,2026) that dilutes existing shareholders.
Short interest is ~23% of shares outstanding as of October30,2026, with 10 days to cover -- a heavy bearish bet against approval or commercial success.
No FDA-approved systemic therapy currently exists for chondrosarcoma, and the FDA could still issue a Complete Response Letter despite positive data.
The stock declined -5% on Q3 earnings day (Nov13,2026) and has fallen from ~$100 in September to the low $80s, showing momentum is negative.
Ozekibart is the only asset under FDA review; a CRL would leave the company with just early-stage pipeline programs and a stretched balance sheet.

Upcoming Catalysts

  • FDA PDUFA decision for ozekibart in unresectable or metastatic conventional chondrosarcoma on April14,2027
  • Potential FDA Advisory Committee meeting (date not yet set)
  • Up to $150M in ATM equity sales that could pressure the stock
  • Update on accelerated approval pathway discussion with FDA for refractory Ewing sarcoma
  • Ongoing Phase1/2 colorectal cancer data updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Inhibrx Biosciences, Inc. PRESS-RELEASE INBX ·Originating report

Sources · 12

Hover a chip for the title
1 finanznachrichten.de2 empr.com3 prnewswire.com4 cancernetwork.com5 healio.com6 seekingalpha.com7 nasdaq.com8 markets.financialcontent.com9 cancernetwork.com10 sec.gov11 newswise.com12 seekingalpha.com